All In Biotech

Drug Trial Radar · NCT00350415

A Double Blind Study for the Treatment of Acute Ulcerative Colitis

A Double-blind, Randomized, 6-week, Parallel-group Design Clinical Trial to Assess the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day for the Treatment of Moderately Active Ulcerative Colitis.

Last checked: Nov 19, 2026Latest source record: Apr 17, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 772 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

772

Actual

Start

Jun 2006

Primary completion

May 2007

Study completion May 2007

Sponsor

Lead sponsor
Warner ChilcottIndustry
Sponsor type
Industry
First posted
Jul 10, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Double-blind, Randomized, 6-week, Parallel-group Design Clinical trial to assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis (ASCEND III).

Conditions

  • Ulcerative Colitis

Interventions

  • MesalamineDrug

    Asacol 400g/day (400 mg tablet), oral, for 6 weeks OR Asacol 4,8 g/day (800 mg table), oral, for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients (ITT) in each treatment group who achieve treatment success, defined as symptomatic and endoscopic improvement from baseline at Week 6.Time frame: Week 6

Locations

135 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Facility

    Alabaster, Alabama

  • Research Facility

    Birmingham, Alabama

  • Research Facility

    Tucson, Arizona

  • Research Facility

    Fayetteville, Arkansas

  • Research Facility

    Little Rock, Arkansas

  • Research Facility

    Anaheim, California

  • Research Facility

    Burbank, California

  • Research Facility

    Encinitas, California

  • Research Facility

    Los Angeles, California

  • Research Facility

    Los Angeles, California

  • Research Facility

    Mission Hills, California

  • Research Facility

    Orange, California

  • Research Facility

    Pasadena, California

  • Research Facility

    Roseville, California

  • Research Facility

    Sacramento, California

  • Research Facility

    San Carlos, California

  • Research Facility

    San Francisco, California

  • Research Facility

    Lakewood, Colorado

  • Research Facility

    Littleton, Colorado

  • Research Facility

    Hamden, Connecticut

  • Research Facility

    DeLand, Florida

  • Research Facility

    Harbor Village, Florida

  • Research Facility

    Hollywood, Florida

  • Research Facility

    Jacksonville, Florida

  • Research Facility

    Panama City, Florida

  • Research Facility

    Zephyrhills, Florida

  • Research Facility

    Atlanta, Georgia

  • Research Facility

    Savannah, Georgia

  • Research Facility

    Arlington Heights, Illinois

  • Research Facility

    Chicago, Illinois

  • Research Facility

    Topeka, Kansas

  • Research Facility

    Louisville, Kentucky

  • Research Facility

    Baton Rouge, Louisiana

  • Research Facility

    Shreveport, Louisiana

  • Research Facility

    Baltimore, Maryland

  • Research Facility

    Chevy Chase, Maryland

  • Research Facility

    Reisterstown, Maryland

  • Research Facility

    Boston, Massachusetts

  • Research Facility

    Columbia, Michigan

  • Research Facility

    Minneapolis, Minnesota

Showing 40 of 135 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.